Dedifferentiated peripheral chondrosarcoma is a rare subtype of chondrosarcoma arising superimposed on the cartilage cap of a preexisting osteochondroma. It consists of two clearly defined components, a low-grade malignant, well-differentiated cartilage component and a high-grade non-cartilaginous sarcoma. Signaling pathways having a role in normal cartilage development were analyzed in these tumors, and compared with available data of other cartilaginous tumors. Sixteen well-characterized dedifferentiated peripheral chondrosarcomas were immunohistochemically analyzed for parathyroid hormone-like hormone (PTHLH)-BCL-2, fibroblastic growth factor (FGF), and transforming growth factor-b signaling molecules, as well as matrix molecules and p53, comparing the chondrogenic component of dedifferentiated peripheral chondrosarcomas with the anaplastic component and with previously published data obtained from conventional grade I and II secondary peripheral chondrosarcomas. Results were correlated with clinical outcome. In the anaplastic component, various lines of differentiation could be found (collagen I (6/16), CD31 (1/16), smooth muscle actin (12/16), muscle-specific actin (12/16) and desmin (2/9)). Compared with the anaplastic component, the chondrogenic component of dedifferentiated peripheral chondrosarcomas shows more often expression of cyclin D1 (P ¼ 0.05), p53 (P ¼ 0.008), plasminogen activator inhibitor 1 (PAI-1) (P ¼ 0.005), and CD44 (P ¼ 0.030). Compared with secondary peripheral chondrosarcomas, more samples were positive in the chondrogenic component of dedifferentiated peripheral chondrosarcomas for FGF signaling (FGF receptor 3 P ¼ 0.000; bFGF P ¼ 0.003) and CD44 (P ¼ 0.000). Lower expression of BCL-2 (P ¼ 0.025) and absence of CD44v3 (P ¼ 0.000), a splice variant of CD44, was observed in the chondrogenic component of dedifferentiated peripheral chondrosarcomas compared with secondary peripheral chondrosarcomas. With regard to clinical data, PAI-1 expression in the chondrogenic component of dedifferentiated peripheral chondrosarcomas correlated with better survival (P ¼ 0.019). In conclusion, in the chondrogenic component of dedifferentiated peripheral chondrosarcomas, FGF signaling pathway is active, whereas PTHLH signaling seems to be low/downregulated. Interestingly, although the chondrogenic component of dedifferentiated peripheral chondrosarcoma is CD44 þ / CD44v3À, secondary peripheral chondrosarcomas is CD44À/CD44v3 þ , which suggest different splicing (preference). The prognostic value of PAI-1 in dedifferentiated peripheral chondrosarcomas might also be of interest for the more common dedifferentiated central chondrosarcomas.
Most chondrosarcomas are well-differentiated conventional low-grade tumors, either arising centrally in the bone (central chondrosarcomas) or at the periphery, secondary to osteochondroma (secondary peripheral chondrosarcomas). 1 About 10% of the chondrosarcomas are dedifferentiated chondrosarcomas, nearly exclusively of the central subtype. 2 The very small proportion consisting of peripheral dedifferentiated chondrosarcomas arise from lowgrade chondrosarcomas originating from the cartilage cap of a preexisting benign osteochondroma (Figure 1a-c) . 3 Osteochondroma is a benign bony outgrowth covered by a cartilaginous cap, of which the solitary sporadic form is about six times more common than the occurrence within the context of multiple osteochondromas. Multiple osteochondromas (previously known as hereditary multiple exostoses) is an autosomal dominant disorder. In both solitary and multiple osteochondromas, the EXT1 and/or EXT2 genes are affected on the genomic level, by mutation and/or deletions. 4, 5 The incidence of dedifferentiated peripheral chondrosarcomas is not very well documented, but from the two largest available series (Mayo clinic, Rochester, MN, USA and Rizzoli Institute, Bologna, Italy) the percentage of dedifferentiated peripheral chondrosarcomas among all dedifferentiated chondrosarcomas is 3.8 6 and 5.5%, 7 respectively. Currently, 49 cases of dedifferentiated peripheral chondrosarcomas have been reported in literature, of which 20 occurred in patients with multiple osteochondromas. 3, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Dedifferentiated chondrosarcomas consist of two clearly defined components, a low-grade, welldifferentiated cartilage tumor (low-grade peripheral chondrosarcoma in the case of a dedifferentiated peripheral chondrosarcomas) and juxtaposed a high-grade non-cartilaginous sarcoma. The transition between these tumor components is histologically abrupt 2, 21 ( Figure 1f ). Dedifferentiated chondrosarcoma is very aggressive and consequently the prognosis is poor. 22 Metastases are frequently present at diagnosis or are found within 2 years of the diagnosis. The overall 2-year survival is B38% and 5-year survival is B24%, but only 10% of the patients with distant metastasis at diagnosis survive for 2 years. 23 Most of these tumors are resistant to chemotherapy. [24] [25] [26] Little information is known about the molecular characterization of dedifferentiated chondrosarcomas. It was shown that central dedifferentiated chondrosarcomas have a monoclonal origin, with an early diversion into the two tumor components. 27 Protein expression studies have been carried out on only a limited number of samples (ranging from 2 to 15 samples, irrespective of the central/peripheral location). [28] [29] [30] [31] [32] The aim of this study was to elucidate the line of differentiation, if present, of the anaplastic component of dedifferentiated peripheral chondrosarcomas. Further, we studied fibroblastic growth factor (FGF), parathyroid hormone-like hormone (PTHLH), and transforming growth factor beta (TGF-b) cellsignaling pathways that are known to have an important role in normal chondrocyte proliferation and differentiation and that are hypothesized to be affected by inactivated EXT, in both the chondrogenic and anaplastic component of dedifferentiated peripheral chondrosarcomas. 
Materials and methods

Patient Samples
Patient charts, histological slides, and radiographs were available at the Rizzoli Institute in Bologna; 14 patients were treated at the Rizzoli Institute, and 2 patients were referred to the Rizzoli Institute for consultation. The samples were part of a study in which the clinical data were published previously. 7 Patient details can be found in Table 1 . All tissue samples were handled in a coded fashion, according to the Dutch National Ethical Guidelines ('Code for Proper Secondary Use of Human Tissue', Dutch Federation of Medical Scientific Societies). The slides were reviewed by three bone tumor pathologists (FB, JVMGB, and PCWH).
Immunohistochemistry
Immunohistochemistry was carried out on all cases, as described previously. 33 Details can be found in Table 2 . Immunohistochemical staining for musclespecific actin, smooth muscle actin, desmin, collagen type 1 (Col I), and CD31 (angiogenic marker) was used to determine a line of differentiation of the anaplastic component (osteogenic-like, myo(fibro)-blastic, or angiogenic) in dedifferentiated peripheral chondrosarcomas. PTHLH signaling was studied using immunohistochemistry for PTHLH, PTH receptor 1 (PTHR1), BCL-2, and cyclin D1. For FGF signaling, fibroblastic growth factor receptor 3 (FGFR3) and bFGF (also known as FGF2) were stained. TGF-b signaling was investigated using TGF-b and plasminogen activator inhibitor 1 (PAI-1) expression. CD44, a cell surface glycoprotein, and CD44v3, an oncogenic splice variant of CD44 carrying a heparan sulphate proteoglycan (HSPG) side chain, were investigated. Scoring was performed as described. 33 The chondrogenic and anaplastic component were evaluated separately. In brief, staining intensities (0 ¼ negative, 1 ¼ weak, 2 ¼ moderate, and 3 ¼ strong intensity) and percentage of positive cells (0 ¼ 0%, 1 ¼ 1-24%, 2 ¼ 25-49%, 3 ¼ 50-74%, and 4 ¼ 75-100% positive) or in case of collagen type I staining distribution (1 ¼ focal and 2 ¼ diffuse) were assessed. The samples were scored positive if the combined values of staining intensity and percentage of positive cells or staining distribution were 43 for PTHLH, PTHR1, BCL-2, p53, FGFR3, bFGF, TGF-b, PAI-1, and Col I, and 40 for cyclin D1, muscle-specific actin, smooth muscle actin, desmin, CD31, CD44, and CD44v3, as previously published.
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Meta-analysis
Results of this study were compared with previously published results on a series of 44 secondary peripheral chondrosarcomas grade I and II.
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Statistical Analysis
Statistical analysis was carried out using SPSS 14.0.1. Statistical significance was defined as Po0.05.
Results
Patient Population Description
The patient group consisted of 12 males and 4 females with a mean age of 43.4 years at diagnosis (range 22-74 years), of which clinical details were described previously. 7 All tumors were both histologically and radiologically proven to originate from a preexisting osteochondroma (for details see Table 1 ).
Immunohistochemical Analysis
Expression of differentiation-related molecules Thirteen out of sixteen dedifferentiated peripheral chondrosarcomas showed myo(fibro)blastic differentiation of the anaplastic component, as was shown by expression of muscle-specific actin and/ or smooth muscle actin and the absence of CD31 (two positive for SMA, MSA, and collagen type I; one positive for muscle-specific actin, smooth muscle actin, and desmin; eight positive for muscle-specific actin and smooth muscle actin; one positive for muscle-specific actin and collagen type I; one positive for only smooth muscle actin). The two tumors showing osteogenic differentiation, as determined by examination of the H&E section were negative for muscle-specific actin, smooth muscle actin, and CD31 (one was positive for collagen type I and desmin, one positive for only collagen type I). One dedifferentiated peripheral chondrosarcoma displayed angiogenic differentiation of the anaplastic component as shown by the expression of CD31 (positive for collagen type I and CD31). Results are summarized in Tables 1 and 3 .
Expression of signaling pathway molecules Dedifferentiated peripheral chondrosarcomas showed the expression of FGF signaling molecules in 92-100% of the tumors, both in the chondrogenic as well as in the anaplastic component. In contrast, expression was only found in up to one-third of conventional secondary peripheral chondrosarcomas. In addition, PTHLH signaling differed between dedifferentiated peripheral chondrosarcomas and conventional secondary peripheral chondrosarcoma; expression of BCL-2 was remarkably absent in dedifferentiated peripheral chondrosarcomas, although found in over half of the secondary peripheral chondrosarcomas (P ¼ 0.025, Fisher's exact test). The cell surface protein CD44, which was absent in secondary peripheral chondrosarcoma, was found in the chondrogenic component of 9 of 13 dedifferentiated peripheral chondrosarcomas Table 4 ).
Correlation with patient outcome PAI-1 expression in the chondrogenic component was the only staining with prognostic value (P ¼ 0.019, univariate log-rank Mantel Cox test, Figure 3 ). Although numbers are small, our data suggest that patients with absence of PAI-1 expression in the chondrogenic component have an increased risk on metastasis and subsequent death.
Discussion
Dedifferentiated chondrosarcomas are rare, and comprise B10% of all chondrosarcomas.
2 Interestingly, of all dedifferentiated chondrosarcomas, only B3.8-5.5% is of the peripheral subtype. 6, 7 This is much lower than one would estimate on the basis of the frequency of secondary peripheral chondrosarcomas, which comprise of B17% of all conventional chondrosarcomas. This emphasizes that dedifferentiation is a rare event in peripheral chondrosarcoma as compared with central chondrosarcoma. The reason for this lower rate of dedifferentiation in peripheral chondrosarcoma remains unclear.
In the past it was unclear whether conventional secondary peripheral chondrosarcomas could develop into dedifferentiated chondrosarcomas, similar to its central counterpart. Currently, sufficient evidence has been proposed to support that this may happen on rare occasions. 3, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] It is sometimes difficult to rule out the possibility that another second malignancy is found in an osteochondroma. [36] [37] [38] [39] [40] In our series of 16 dedifferentiated peripheral chondrosarcomas, we show that the anaplastic component most often displays myo(fibro)blastic differentiation in its so-called dedifferentiated component, as could be determined from the musclespecific actin and smooth muscle actin staining. It is important to realize that the anaplastic component can also show desmin positivity, as we found in 2 of 16 cases, to avoid confusion with leiomyosarcoma in the diagnostic practice. Interestingly, although in dedifferentiated peripheral chondrosarcomas, myofibroblastic differentiation is most common in the anaplastic component, in dedifferentiated central chondrosarcomas the majority of the anaplastic components is of the so-called osteogenic subtype. 25 The line of differentiation within the anaplastic component is important, as the anaplastic component determines the clinical behavior and therefore guides possible choices of chemotherapy or future targeted therapy.
In peripheral chondrosarcomas, the EXT1 and/or EXT2 genes are affected on the genomic level, by mutation and/or deletions, 4, 5 leading to aberrant HSPG synthesis. 41 HSPGs are involved in signal transduction of several pathways, including the hedgehog, TGF-b, and FGF signaling. 42, 43 We studied the expression of growth plate signaling molecules in the PTHLH-BCL-2, FGF, and TFG-b signaling pathways, which have been extensively studied in other cartilaginous tumors. [34] [35] [36] [44] [45] [46] [47] In addition, the expression of matrix molecules was studied and the expression in the two components was compared. These signaling molecules have an important role in the growth and differentiation of the normal growth plate and could therefore be of importance in the cartilaginous tumor development and tumor progression. For instance, expression of PTHLH and BCL-2 was found to be of diagnostic value in the distinction between osteochondroma and low-grade secondary peripheral chondrosarcoma, with low or absent expression in the osteochondromas. 44 Differences in expression between the chondrogenic and anaplastic component were found in molecules related to cell cycle regulation (cyclin D1) and p53 (apoptosis). Upregulation of the cell cycle in the anaplastic component is to be expected, as this component is highly active with more mitoses present compared with the chondrogenic component. In addition, the upregulation of p53, most likely a mutated, inactive form is often seen in high-grade tumors, as is also observed previously in high-grade chondrosarcomas and dedifferentiated chondrosarcomas (reviewed in Rozeman et al. 28 ) Comparison of the chondrogenic component of the peripheral dedifferentiated chondrosarcomas with the secondary peripheral chondrosarcomas grade I and II, which match the stage of the chondrogenic component found in dedifferentiated chondrosarcomas, revealed some interesting differences. In the dedifferentiated chondrogenic component, the FGF signaling is higher, 33 as well as the CD44 expression. 35 On the other hand, expressions of PTHLH, BCL-2, p53, and CD44v3 are low. [33] [34] [35] 44 The higher expression of the FGF signaling and altered expression status of CD44/CD44v3, when comparing the chondrogenic component of dedifferentiated peripheral chondrosarcomas with conventional secondary peripheral chondrosarcomas, suggests that these changes maybe of importance in the transformation of chondrosarcoma toward dedifferentiated chondrosarcoma, which unfortunately is canceled out by the anaplastic component.
Increased PAI-1 expression in the anaplastic component as seen in this paper was also observed previously in conventional dedifferentiated chondrosarcomas. 48 It is interesting that the expression of PAI-1 in the cartilaginous component of dedifferentiated peripheral chondrosarcomas is related to good prognosis, although these are small numbers. PAI-1 is partly regulated by TGF-b. 49, 50 PAI-1 has many functions in the cell and is able to influence cell motility in several ways, such as by binding to the adhesive glycoprotein vitronectin and detaching cells from (a variety of) matrix proteins by inducing the internalization of adhesion receptors. 51 PAI-1 also has a role in the process of angiogenesis. 51 Although at first glance the PAI-1/TGF-b signaling might be a good candidate to start looking for therapy, one should consider that the prognostic PAI-1 expression is localized in the cartilage component, which is notoriously hard to treat, 22 as there are limited ways to reach the cells in this compartment. In addition, PAI-1 is downstream of not only TGF-b signaling but also of EGFR signaling. 52 Targeting of PAI-1 by, for instance, blocking HER-1 (upstream of PAI-1) was found to be of limited success in sarcomas, such as synovial sarcomas, 53 but would required further experiments in case of dedifferentiated peripheral chondrosarcomas.
The upregulation of CD44 is seen in the anaplastic component compared with the chondrogenic component of dedifferentiated chondrosarcomas. CD44 is a transmembrane glycoprotein, involved in the regulation of growth, differentiation, survival, and cell motility. 54 Misregulation of CD44, resulting in expression of different splice variants, is related to poor prognosis in many cancers, 54 and is also seen in high-grade secondary peripheral chondrosarcomas. 35 Patients with dedifferentiated chondrosarcomas have a bad prognosis, with B62% dying within 2 years, and in case of patients with distant metastasis at diagnosis 90% die within 2 years. 23 In the current patient group, all patients with distant metastasis died within 2 years of their documentation. In all, 5 of the 16 patients had no evidence of disease after the first 2 years, one of them later still developed metastasis and died. One patient was lost to followup after 22 months, but had at that time also no evidence of disease. As most data in literature are derived from conventional dedifferentiated chondrosarcoma, which are more common than peripheral dedifferentiated chondrosarcomas, 3, 6, 7 there might be different behavior for conventional central and peripheral dedifferentiated chondrosarcomas.
In conclusion, first, differences in expression between the chondrogenic component of dedifferentiated peripheral chondrosarcoma and secondary peripheral chondrosarcoma are present, such as CD44/CD44v3 and FGF signaling, and these might provide clues in the future to which secondary peripheral chondrosarcomas can develop into dedifferentiated chondrosarcomas. Second, as expression of actin markers is present in the majority of the dedifferentiated peripheral chondrosarcomas, care should be taken to avoid misdiagnosis of, for instance, a leiomyosarcoma based on small biopsy samples. Third, a potential prognostic marker was identified, in which PAI-1 expression in the chondrogenic component of the dedifferentiated peripheral chondrosarcoma is correlated with a good prognosis. However, only a small number of samples were available and this might influence the data.
